Congress has returned to Capitol Hill, and among the most important unfinished business on its agenda is agreeing to a new package to fight COVID-19 by funding second-generation vaccine research. When Congress left town, there was cautious optimism that a deal was close.
Your Chance to Pitch: Applications Open for Rocky Mountain Life Sciences Companies
Thirty regional companies will be selected to present at the Rocky Mountain Life Sciences Investor & Partnering Conference. Companies seeking seed, early-stage, late-stage funding in the medical device, diagnostic, biotech, pharmaceutical, and digital health sectors are encouraged to apply.
What’s with that new label?
With new labeling requirements, bioengineering entered consumer consciousness in a new way this year—but people are learning the benefits, according to Sarah Gallo, BIO’s VP of Agriculture and Environment, in this podcast.
Can biotech be harnessed?
From the NIne Questions for the World podcast, December 15, 2021. BIO President Michelle McMurray-Heath is interviewed by Richard Haass.